{"id":"https://openalex.org/W4367304527","doi":"https://doi.org/10.1212/wnl.0000000000203311","title":"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures (P11-1.012)","display_name":"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures (P11-1.012)","publication_year":2023,"publication_date":"2023-04-25","ids":{"openalex":"https://openalex.org/W4367304527","doi":"https://doi.org/10.1212/wnl.0000000000203311"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000203311","doi":"https://doi.org/10.1212/wnl.0000000000203311","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000203311","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026329899","display_name":"Ant\u00f3nio Gil\u2010Nagel","orcid":"https://orcid.org/0000-0003-4515-0793","observed_orcids":["https://orcid.org/0000-0003-4515-0793"]},"institutions":[{"id":"https://openalex.org/I4210150844","display_name":"Hospital Ruber Internacional","ror":"https://ror.org/04abjq359","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210150844"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Antonio Gil-Nagel","raw_affiliation_strings":["Hospital Ruber Internacional, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Ruber Internacional, Madrid, Spain","institution_ids":["https://openalex.org/I4210150844"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000233437","display_name":"David G. Vossler","orcid":"https://orcid.org/0000-0003-4823-0537","observed_orcids":["https://orcid.org/0000-0003-4823-0537"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210106811","display_name":"Valley Medical Center","ror":"https://ror.org/01vjngb81","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210106811"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Vossler","raw_affiliation_strings":["University of Washington, Seattle and UW Medicine/Valley Medical Center, Renton, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington, Seattle and UW Medicine/Valley Medical Center, Renton, WA, USA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210106811"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061862920","display_name":"Elinor Ben\u2010Menachem","orcid":"https://orcid.org/0000-0001-5864-9185","observed_orcids":["https://orcid.org/0000-0001-5864-9185"]},"institutions":[{"id":"https://openalex.org/I881427289","display_name":"University of Gothenburg","ror":"https://ror.org/01tm6cn81","country_code":"SE","type":"education","lineage":["https://openalex.org/I881427289"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Elinor Ben-Menachem","raw_affiliation_strings":["Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden","institution_ids":["https://openalex.org/I881427289"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023079240","display_name":"William Curt LaFrance Jr","orcid":"https://orcid.org/0000-0002-4901-3852","observed_orcids":["https://orcid.org/0000-0002-4901-3852"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]},{"id":"https://openalex.org/I2800446032","display_name":"Rhode Island Hospital","ror":"https://ror.org/01aw9fv09","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800446032","https://openalex.org/I4210151747"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. LaFrance","raw_affiliation_strings":["Rhode Island Hospital, Brown University, and VA Providence Health Care System, Providence, RI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rhode Island Hospital, Brown University, and VA Providence Health Care System, Providence, RI, USA","institution_ids":["https://openalex.org/I27804330","https://openalex.org/I2800446032"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080677331","display_name":"Cynthia L. Harden","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127345","display_name":"Xenon Pharmaceuticals (Canada)","ror":"https://ror.org/029t2gr02","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210127345"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Cynthia Harden","raw_affiliation_strings":["Xenon Pharmaceuticals Inc., Burnaby BC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xenon Pharmaceuticals Inc., Burnaby BC, Canada","institution_ids":["https://openalex.org/I4210127345"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014981660","display_name":"Jenny Qian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127345","display_name":"Xenon Pharmaceuticals (Canada)","ror":"https://ror.org/029t2gr02","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210127345"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Jenny Qian","raw_affiliation_strings":["Xenon Pharmaceuticals Inc., Burnaby BC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xenon Pharmaceuticals Inc., Burnaby BC, Canada","institution_ids":["https://openalex.org/I4210127345"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067874225","display_name":"Gregory N. Beatch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127345","display_name":"Xenon Pharmaceuticals (Canada)","ror":"https://ror.org/029t2gr02","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210127345"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Gregory Beatch","raw_affiliation_strings":["Xenon Pharmaceuticals Inc., Burnaby BC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xenon Pharmaceuticals Inc., Burnaby BC, Canada","institution_ids":["https://openalex.org/I4210127345"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083994450","display_name":"Christopher Kenney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127345","display_name":"Xenon Pharmaceuticals (Canada)","ror":"https://ror.org/029t2gr02","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210127345"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Christopher Kenney","raw_affiliation_strings":["Xenon Pharmaceuticals Inc., Burnaby BC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Xenon Pharmaceuticals Inc., Burnaby BC, Canada","institution_ids":["https://openalex.org/I4210127345"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2041,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.49916417,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"100","issue":"17_supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10493","display_name":"Ion channel regulation and function","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/primary-generalized-tonic-clonic-seizures","display_name":"primary generalized tonic-clonic seizures","score":0.9599999785423279},{"id":"https://openalex.org/keywords/adjunctive-antiepileptic-therapy","display_name":"adjunctive antiepileptic therapy","score":0.8899999856948853},{"id":"https://openalex.org/keywords/seizure-frequency-reduction","display_name":"seizure frequency reduction","score":0.7789999842643738},{"id":"https://openalex.org/keywords/epilepsy","display_name":"epilepsy","score":0.6110000014305115},{"id":"https://openalex.org/keywords/photosensitivity","display_name":"photosensitivity","score":0.609000027179718},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.7860000133514404},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6769999861717224},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.6240000128746033},{"id":"https://openalex.org/keywords/seizure-freedom","display_name":"seizure freedom","score":0.4350000023841858},{"id":"https://openalex.org/keywords/patient-global-impression-of-change","display_name":"Patient Global Impression of Change","score":0.8600000143051147},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.44999998807907104}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7163748145103455},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6574252247810364},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5985150337219238},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5822331309318542},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.5555911064147949},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.47570309042930603},{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.45755019783973694},{"id":"https://openalex.org/C3018162438","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Adjunctive treatment","level":2,"score":0.45645734667778015},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4376031160354614},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.42521733045578003},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3344039022922516},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32111626863479614},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.09606531262397766},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000203311","doi":"https://doi.org/10.1212/wnl.0000000000203311","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000203311","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8199999928474426,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Study Protocol","id":"https://openalex.org/study-designs/study-protocol"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4387439518","https://openalex.org/W4389374282","https://openalex.org/W4367303360","https://openalex.org/W4394598647","https://openalex.org/W4285684695","https://openalex.org/W4394598661","https://openalex.org/W4409234829","https://openalex.org/W3159562706","https://openalex.org/W1990788850","https://openalex.org/W4393947540"],"abstract_inverted_index":{"Objective:":[0],"Describe":[1],"the":[2,18,29,85,93,112,120,170,205,222,276,287,300,312,330,349,368,393,417,442,468,493,518,538,558,578,598,618,639,659,727,746,808,826,844,869,907],"rationale":[3,94],"and":[4,20,91,115,221,237,245,257,263,279,291],"study":[5,15,109],"design":[6],"of":[7,22,31,89,117,132,207,226,239,281,289,297,302,314,332,351,370,395,419,444,470,495,520,540,560,580,600,620,641,661,674,686,698,709,729,748,766,779,791,810,828,846,871,891,909,922,931,970,993,1007],"X-ACKT,":[8],"a":[9,40,63,96,102,129,154,182,319,337,356,375,400,424,449,475,500,525,545,565,585,605,625,646,666,734,753,815,833,851,940,953,1027],"randomized,":[10,106],"double-blind,":[11,107],"placebo-controlled":[12,108],"Phase":[13,103],"3":[14],"to":[16,110,153,164,229,294,943,956,1032,1039],"evaluate":[17,111],"safety":[19,114],"efficacy":[21,116,188,280],"XEN1101":[23,38,90,118,282,298],"as":[24,283,318,336,355,733,814,832,875,913,967,990,1004],"an":[25,136,160,176,876,914,968,991,1005],"adjunctive":[26,284],"therapy":[27,285],"in":[28,54,70,119,123,194,212,251,286,311,329,348,367,392,416,441,467,492,517,537,557,577,597,617,638,658,726,745,807,825,843,868,906,978,1015],"treatment":[30,240,288,301],"primary":[32,187],"generalized":[33],"tonic-clonic":[34],"seizures":[35],"(PGTCS).":[36],"Background:":[37],"is":[39,101,190,292],"novel,":[41],"potent,":[42],"selective":[43],"Kv7.2/7.3":[44],"potassium":[45,65],"channel":[46,66],"opener":[47,67],"which":[48],"shows":[49],"broad":[50],"spectrum":[51],"seizure":[52,130,166,219],"suppression":[53],"preclinical":[55],"models.":[56],"In":[57],"epilepsy":[58],"patients":[59],"with":[60,128],"photosensitivity,":[61],"ICA-105665,":[62],"Kv7":[64],"no":[68],"longer":[69],"development,":[71],"suppressed":[72],"paroxysmal":[73],"EEG":[74],"activity":[75],"(Kasteleijn-Nolst":[76],"Trenit\u00e9":[77],"et":[78],"al,":[79],"Epilepsia.":[80],"2013;54(8)).":[81],"These":[82],"data":[83],"support":[84,295,680,692,704,715,772,785,797,897,928],"broad-spectrum":[86],"anti-seizure":[87],"potential":[88],"provide":[92,273],"for":[95,175,299,316,321,334,339,353,358,372,383,397,408,421,432,446,457,472,483,497,508,522,528,542,548,562,568,582,588,602,608,622,628,643,649,663,669,731,736,750,761,812,817,830,835,848,859,873,885,911,917,965,988,1002],"PGTCS":[97,134,196,214,290],"trial.":[98],"Design/Methods:":[99],"X-ACKT":[100,271],"3,":[104],"multicenter,":[105],"PK,":[113],"fed":[121],"state":[122],"adults":[124],"aged":[125],"18\u201375":[126],"years":[127],"frequency":[131,197,215,238],"\u22653":[133],"over":[135],"8-week":[137,161],"baseline,":[138],"taking":[139],"1\u20133":[140],"antiseizure":[141],"medications":[142],"(ASMs).":[143],"Approximately":[144],"160":[145],"subjects":[146,208],"will":[147,232,266,272],"be":[148,173,233,268],"randomized":[149],"at":[150],"1:1":[151],"(25mg:placebo)":[152],"12-week":[155],"double-blind":[156],"period":[157,163],"(DBP)":[158],"following":[159],"baseline":[162,217],"assess":[165],"frequency.":[167],"Subjects":[168],"completing":[169],"DBP":[171],"may":[172],"eligible":[174],"open-label":[177],"extension":[178],"(OLE)":[179],"trial":[180],"under":[181],"separate":[183],"protocol.":[184],"Results:":[185],"The":[186,200,672,684,696,707,764,777,789,889,920],"endpoint":[189],"median":[191],"percent":[192],"change":[193],"monthly":[195,213],"from":[198,216,681,693,705,716,773,786,798,898,929,939,952,1026],"baseline.":[199,230],"key":[201],"secondary":[202],"outcomes":[203],"are":[204],"proportion":[206],"experiencing":[209],"\u226550%":[210],"reduction":[211],"(RR50),":[218],"freedom":[220],"Patient":[223],"Global":[224],"Impression":[225],"Change":[227],"compared":[228],"Safety":[231,380,405,429,454,480,505,758,856],"evaluated":[234],"by":[235],"severity":[236],"emergent":[241],"adverse":[242],"events":[243],"(AEs)":[244],"serious":[246],"AEs;":[247],"clinically":[248],"significant":[249],"changes":[250],"clinical":[252],"laboratory":[253],"findings,":[254],"physical,":[255],"neurologic":[256],"ophthalmologic":[258],"exams,":[259],"ECGs,":[260],"vital":[261],"signs,":[262],"urinary":[264],"symptoms":[265],"also":[267],"evaluated.":[269],"Conclusions:":[270],"insight":[274],"into":[275],"safety,":[277],"tolerability,":[278],"designed":[293],"registration":[296],"PGTCS.":[303],"Disclosure:":[304],"Dr.":[305,323,342,361,386,410,435,461,486,511,531,551,571,591,611,632,652,675,687,699,710,720,739,767,780,792,801,819,837,862,892,900,923,933,946,959,974,996,1011,1019],"Gil-Nagel":[306,324,343,362,387,411,436,462,487,512,532,552,572,592,612,633,653,676,688,700,711],"has":[307,325,344,363,388,412,437,463,488,513,533,553,573,593,613,634,654,677,689,701,712,722,741,769,782,794,803,821,839,864,894,902,925,935,948,961,976,984,998,1013,1021,1037],"received":[308,326,345,364,389,413,438,464,489,514,534,554,574,594,614,635,655,678,690,702,713,723,742,770,783,795,804,822,840,865,895,903,926,936,949,962,985,999,1022],"personal":[309,327,346,365,390,414,439,465,490,515,535,555,575,595,615,636,656,724,743,805,823,841,866,904,963,986,1000],"compensation":[310,328,347,366,391,415,440,466,491,516,536,556,576,596,616,637,657,725,744,806,824,842,867,905,964,987,1001],"range":[313,331,350,369,394,418,443,469,494,519,539,559,579,599,619,640,660,728,747,809,827,845,870,908],"$500-$4,999":[315,333,371,396,420,445,471,521,541,561,601,621,642,662,730,749,811,829,847],"serving":[317,335,354,373,398,422,447,473,498,523,543,563,583,603,623,644,664,732,751,813,831,849,874,912,966,989,1003],"Consultant":[320,338,357,735,816,834],"Biocodex.":[322],"EISAI":[340,569],".":[341,460,485,510,550,570,631,671],"$0-$499":[352],"GW":[359,433,589,860],"Pharma.":[360,385,434,530,590,610,651,861],"on":[374,399,423,448,474,499,524,544,564,584,604,624,645,665,752,850],"Scientific":[376,401,425,450,476,501,754,852],"Advisory":[377,402,426,451,477,502,755,853,882],"or":[378,403,427,452,478,503,756,854,880,1029],"Data":[379,404,428,453,479,504,757,855],"Monitoring":[381,406,430,455,481,506,759,857],"board":[382,407,431,456,482,507,760,858],"Angelini":[384,529],"EISAI.":[409],"PTC":[458,629,694],"Therapeutics":[459,630],"Stoke":[484],"$5,000-$9,999":[496,581],"Zogenix":[509,670],"Speakers":[526,546,566,586,606,626,647,667],"Bureau":[527,547,567,587,607,627,648,668],"BIAL":[549],"Jazz":[609,682],"UCB":[650],"institution":[673,685,697,708,765,778,790,890,921],"research":[679,691,703,714,771,784,796,896,927],"Pharmaceuticals.":[683,738,763,788,800,995],"Therapeutics.":[695],"Zogenix.":[706],"Agencia":[717],"Estatal":[718],"Innovacion.":[719],"Vossler":[721,740,768,781,793],"Biocodex":[737],"Longboard":[762,799],"SK":[774],"Life":[775],"Science.":[776],"Xenon":[787,971,979,994,1008,1016],"Ben-Menachem":[802,820,838,863,893],"UCB.":[818],"Arvelle.":[836],"$10,000-$49,999":[872,910],"Editor,":[877,879],"Associate":[878],"Editorial":[881],"Board":[883],"Member":[884],"Acta":[886],"Neurologica":[887],"Scandinvica.":[888],"zogenic.":[899],"LaFrance":[901,924,934,947],"Expert":[915],"Witness":[916],"medico-legal":[918],"work..":[919],"Department":[930],"Defense.":[932],"publishing":[937,950],"royalties":[938,951],"publication":[941,954],"relating":[942,955,1031],"health":[944,957,1033],"care.":[945,958,1034],"Harden":[960,975],"employee":[969,992,1006],"Pharmaceuticals":[972,980,1009,1017],"Inc..":[973,981],"stock":[977,1014],"Ms.":[982],"Qian":[983],"Beatch":[997,1012,1020],"Inc.":[1010,1018],"intellectual":[1023],"property":[1024],"interests":[1025],"discovery":[1028],"technology":[1030],"Christopher":[1035],"Kenney":[1036],"nothing":[1038],"disclose.":[1040]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2023-04-29T00:00:00"}